Research Funding

DOD Orthotics and Prosthetics Outcomes Research Program Funding Opportunities for Fiscal Year 2019

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the FY19 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY19 Focus Areas:

  • Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
  • Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
  • Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

https://cdmrp.army.mil/funding/oporp

 Clinical Research Award – Letter of Intent due July 24 2019

Independent investigators at all academic levels (or equivalent)

  • Supports research that evaluates orthotic and/or prosthetic devices using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment
  • Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
  • Multidisciplinary collaboration among academia, industry, the DoD, the Department of Veterans Affairs (VA), and other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY19 OPORP CRA must address one or more of the FY19 OPORP Focus Areas.
  • Animal studies are not allowed.
  • Clinical trials are not allowed.
  • The FY19 CRA offers two funding levels:

Funding Level 1:

  • Maximum funding of $350,000 for total costs (direct costs plus indirect costs)
  • Maximum period of performance is years

Funding Level 2:

  • Maximum funding of $1,000,000 for total costs (direct costs plus indirect costs)
  • Maximum period of performance is years

Clinical Trial Award – Letter of Intent due July 24, 2019

Independent investigators at all academic levels (or equivalent)

  • Supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of Service members, Veterans, and other individuals living with limb deficit.
  • Supports clinical trials that evaluate orthotic and/or prosthetic devices using patient-centric outcomes.
  • Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
  • Multidisciplinary collaboration among academia, industry, the military Services, the VA, and other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY19 OPORP CTA must address one or more of the FY19 OPORP Focus Areas.
  • Preclinical research is not allowed.

The FY19 CTA offers two funding levels:

Funding Level 1:

  • Maximum funding of $350,000 for total costs (direct costs plus indirect costs)
  • Maximum period of performance is years

Funding Level 2:

  • Maximum funding of $2,000,000 for total costs (direct costs plus indirect costs)
  • Maximum period of performance is years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

DOD Melanoma Research Program Funding Opportunities for Fiscal Year 2019

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP) to support innovative, high-impact melanoma research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 MRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

The FY19 MRP Focus Areas are listed below:

  • Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
  • Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
  • Therapeutic Prevention
  • Minimal Residual Disease
  • Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.

https://cdmrp.army.mil/funding/mrp

Idea Award – Preproposal due July 26, 2019

Independent investigators with a faculty-level appointment (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research.
  • Emphasis on Innovation and Impact
  • Preliminary data are not required.
  • Clinical trials are not allowed.
  • The maximum allowable funding for the entire period of performance is $300,000 for direct costs
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
  • Maximum period of performance is years

Team Science Award – Preproposal due July 26, 2019

At least two and up to three investigators must partner in one overarching multidisciplinary research study.

Initiating Principal Investigator (PI):

Independent investigators at or above the level of Associate Professor (or equivalent).

Partnering PI: Independent investigators at or above the level of Assistant Professor (or equivalent).

Post-doctoral fellows are not eligible to be partnering PIs.

  • Preproposal is required; application submission is by invitation only.
  • Supports new or existing partnerships between two or three independent investigators focusing research across the whole research spectrum.
  • Investigators are expected to demonstrate within the application, the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.
  • Emphasis on Synergy, Multi-disciplinary research, and Impact
  • Inclusion of an independent early career investigator is encouraged.
  • Inclusion of at least one military or U.S. Department of Veterans Affairs (VA) investigator is encouraged.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • The maximum allowable funding for the entire period of performance is $700,000 for direct costs
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
  • Maximum period of performance is years

Translational Research Award – Preproposal is due July 26, 2019

Independent investigators at or above the level of Assistant Professor (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Supports studies aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trials to address a translational question or problem in melanoma.
  • Emphasis on Translation and Impact.
  • Inclusion of DoD or VA participation is encouraged.
  • Preliminary data is required.
  • Clinical trials are not allowed.
  • The maximum allowable funding for the entire period of performance is $600,000 for direct costs
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
  • Maximum period of performance is years

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

DOD Gulf War Illness Research Program Funding Opportunity for Fiscal Year 2019

The FY19 Defense Appropriation provides $22 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support research addressing Gulf War Illness pathobiology, diagnosis, and treatment.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

https://cdmrp.army.mil/funding/gwirp

Idea Award – Preapplication is Due July 12, 2019

Independent investigators at all academic levels

  • Supports innovative high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for Gulf War illness (GWI).
  • Impact and innovation are important review criteria.
  • Preliminary data not
  • Clinical trials not allowed.
  • Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program announcement/Funding Opportunity will qualify for a higher level of funding.  Application to this option is not a requirement for Idea Award submission.
  • Maximum funding of $150,000 for direct costs (plus indirect costs)
  • Maximum funding of $170,000 for direct costs with the Biorepository Contribution Option (plus indirect costs)
  • Maximum period of performance is years
  • Preapplication is required; application submission is by invitation only.

Clinical Evaluation Award – Preapplication due July 12, 2019

Independent investigators at all academic levels

  • Supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population.
  • Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints – or – proof-of-concept intervention trials (e.g., pilot, first in human, Phase I-IIa) are encouraged under this funding opportunity.
  • Preliminary data required.
  • Funding for this award mechanism must support research in a Gulf War Veteran population.  Proof of availability and access to necessary cohort(s) and/or critical reagents must be provided.
  • Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding. Applications to this option is not a requirement for Clinical Evaluation Award submission.
  • Clinical Consortium Collaboration Option: Applications including a commitment to work with the GWIRP-supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Clinical Consortium Collaboration options applications are not eligible to also submit under the Biorepository Contribution Option.  Application to this option not a requirement for Clinical Evaluation Award submission.
  • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • Maximum funding of $1,020,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).
  • Maximum funding of $1,200,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs).
  • Maximum period of performance is 3years
  • Preapplication is required; application submission is by invitation only.

Therapeutic/Biomarker Trial Award – Preapplication due July 12, 2019

Independent investigators at all academic levels

  • Supports large-scale, pivotal (Phase IIb or III) trials that revolutionize the clinical management of GWI.
  • Objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual with Gulf War Veteran or Gulf War Veteran subgroup must be included in the trial design.
  • Investigators must have experience in leading large-scale projects and demonstrated ability to implement a clinical project successfully.
  • Funding must be used to support a clinical trial.
  • Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding. Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.
  • Clinical Consortium Collaboration Option: Applications including a commitment to work with the GWIRP-supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Clinical Consortium Collaboration Option applications are not eligible to also submit under the Biorepository Contribution Option.  Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.
  • Funding must be used to support a clinical trial.
  • Maximum funding of $5,000,000 for direct costs (plus indirect costs)
  • Maximum funding of $5,020.000 for direct costs with the Biorepository Contribution Option (plus indirect costs)
  • Maximum funding of $5,500,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs)
  • Maximum period of performance is 4years
  • Preapplication is required; application submission is by invitation only.

Patient-Provider and Health Communications Award – Preapplication due July 12, 2019

Independent investigators at or above the level of Assistant Professor

  • Supports projects aimed at tools and processes to raise awareness of GWI research and clinical findings within communities, including Veterans with GWI and/or their caregivers or advocates, healthcare providers who serve Veterans with GWI, or public health professional relevant to Veterans with GWI.
  • Maintenance and sustainment of the dissemination effort past the award period for continued awareness of GWI research and clinical findings is an important review criterion.
  • Must include a description of evaluation metrics and tracking to assist in measuring the success of the communication tool or process.
  • Must include at least one Gulf War Veteran with GWI, who will be integral throughout the planning and implementation of the research project.
  • Near-term impact is expected.
  • Clinical trials are not allowed.
  • Maximum funding of $700,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3years
  • Preapplication is required; application submission is by invitation only.

New Investigator Award – Preapplication due July 12, 2019

PIs may apply under one of the following three eligibility categories:

Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training

Early-Career Investigator: Independent investigators within 5 years since their last training position

New GWI Researcher: Established independent investigators who have received less than $300,000 in Federally funded, non-mentored GWI research

  • Encourages applications from early-stage and established investigators new to the field of GWI research.
  • Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers is strongly encouraged.
  • Preliminary data are not
  • Clinical trials are not allowed.
  • Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding, Application to this option is not a requirement for New Investigator award submission.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum funding of $520,000 for direct costs with the Biorepository Contribution Option (plus indirect costs)
  • The maximum period of performance is 3years
  • Preapplication is required; application submission is by invitation only.

Research Advancement Award – Preapplication due July 12, 2019

Independent investigators at all academic levels

  • Supports preclinical research already supported by preliminary or published data in the GWI field that is ready for validation through expansion, replication, or comparative studies.
  • Impact is an important review criterion.
  • Preliminary data in the field of GWI and other supporting information is required.
  • Clinical trials are not allowed.
  • Biorepository Contribution Option: Applications including a commitment to work with the GWIRP-supported Biorepository Resource Network and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  Application to this option is not a requirement for Research Advancement Award submission.
  • Preapplication is required; application submission is by invitation only.
  • Maximum funding of $700,000 for direct costs (plus indirect costs).
  • Maximum funding of $720,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Preapplication is required; application submission is by invitation only.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org